Hong Kong Medical Equipment Stock News

China Resources Land (SEHK:1109) has released its January 2026 operating update, reporting contracted sales of about RMB 11.65b and recurring revenue of RMB 4.51b, giving investors a fresh monthly read on business activity. See our latest analysis for China Resources Land. The January update comes after a solid stretch of gains, with a 1-month share price return of 10.42% and year to date share price return of 12.41%. The 1-year total shareholder return of 31.18% suggests momentum has been...

Tencent Holdings after recent share price weakness Tencent Holdings (SEHK:700) has seen its share price fall around 12% over the past month and about 16% over the past 3 months, prompting investors to reassess what they are paying for its earnings and growth profile. See our latest analysis for Tencent Holdings. Looking beyond the recent pullback, Tencent Holdings’ 30 day share price return of 12.27% and year to date share price return of 16.21% both point to fading momentum, even though the...

Tencent Holdings (SEHK:700) has backed Chinese large language model developer Moonshot, which has gained rapid traction in the AI sector. The company is also an investor in Maya, a fintech firm that is preparing for a potential US IPO as it seeks international expansion. The US Department of Defense recently named, then removed, Tencent from a list of companies it alleged were linked to China’s military, drawing fresh regulatory attention. Tencent operates across consumer internet, gaming,...

Global markets have recently experienced volatility, with U.S. stocks declining amid concerns over AI disruptions and a mixed economic outlook from various regions. Despite these fluctuations, investors continue to seek opportunities that balance value and growth potential. Penny stocks, though an outdated term, remain relevant for those interested in smaller or newer companies with strong financials that may offer significant returns. In this article, we explore three such penny stocks that...

Guidance-driven spotlight on Sihuan Pharmaceutical Holdings Group Sihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance, indicating at least RMB 2,500 million in revenue and RMB 150 million in net profit for the year. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The earnings guidance lands after a strong run in the share price, with a 30 day share price return of 25.19% and a year to date gain of 28.12%...

Insilico Medicine Cayman TopCo announced a new partnership with China Medical System Holdings SEHK:3696 to collaborate on AI powered drug discovery and development. The company also nominated ISM5059, an NLRP3 targeted drug candidate discovered using its AI platform, for preclinical development. These updates follow recent FDA IND approval for another AI created drug in Insilico Medicine's pipeline. For you as an investor, these moves sit at the intersection of AI and pharmaceuticals, where...

Q Technology (Group) (SEHK:1478) has released its January 2026 operating update, reporting monthly sales volumes of 44,071,000 camera modules and 19,741,000 fingerprint recognition modules. This provides investors with a fresh data point on current demand. See our latest analysis for Q Technology (Group). At a share price of HK$8.82, Q Technology (Group) has a 1-year total shareholder return of 12.98% and a 3-year total shareholder return of 86.90%, even though its 30-day share price return...

As global markets grapple with concerns over AI disruptions and mixed economic signals, Asian markets have shown resilience, with Japan's stock indices experiencing significant gains following political developments. In this environment, dividend stocks in Asia offer a compelling option for investors seeking steady income streams; these stocks can provide a buffer against market volatility while potentially yielding attractive returns.

If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. The stock closed at HK$46.68, with a 7 day return of a 2% decline, a 30 day return of an 8% decline and a 1 year return of 23.3%, which may catch the eye of investors thinking about both risk and opportunity. Recent trading interest has been shaped by ongoing attention on the biotech and...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Sinofert Holdings Limited has announced that, effective 13 February 2026, Mr. Su Fu resigned as non-executive director and Chairman, with industry veteran Mr. Zhang Xuegong appointed as executive director, Chairman of the Board and head of the strategy committee. This leadership shift brings the group’s fertilizer, chemical and seed businesses under a chairman who previously held senior roles across Sinochem’s agricultural value chain, potentially reshaping how Sinofert aligns with its...

Minth Group (SEHK:425) has drawn fresh attention after announcing two North American joint ventures: one focused on aluminum body frame parts in Canada and another on humanoid robot joint modules in the United States. See our latest analysis for Minth Group. The recent North American joint venture announcements align with strong momentum in the stock, with a 36.28% 1-month share price return and a very large 1-year total shareholder return, suggesting investors are reassessing Minth Group's...

As global markets navigate the complexities of AI disruption and fluctuating economic indicators, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to provide potential value for those willing to explore beyond mainstream investments. Despite the term's outdated connotations, these stocks can offer significant growth when backed by strong financials. In this article, we explore...

Bank of East Asia (SEHK:23) has drawn investor attention after reporting full year 2025 earnings, with lower net income and a reduced second interim dividend, alongside additional impairment charges and a one off loss at associate Guotong Trust. See our latest analysis for Bank of East Asia. The latest results and dividend cut arrived alongside sharp price swings, with a 7.57% 1 day share price return after the announcement, a 30 day share price return of 11.18%, and a 1 year total...

AIA Group Limited has appointed Ms. Shulamite N K Khoo and Mr. Ku Man as Independent Non-executive Directors to its board, effective 5 February 2026, drawing on their extensive experience across Asian financial services, technology and human capital management. The addition of Ms. Khoo, a former AIA Group Chief Human Resources Officer, and Mr. Ku, Chairman of WeBank, strengthens the board’s governance depth and digital financial expertise at a time when regional insurers are adapting to...

CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after securing regulatory clearance to begin clinical trials for two long acting drug candidates targeting obesity, weight related conditions, and post operative pain. See our latest analysis for CSPC Pharmaceutical Group. The recent regulatory clearances arrive after a strong run, with CSPC Pharmaceutical Group’s 90 day share price return of 35.40% and 1 year total shareholder return of 118.26% pointing to building momentum...

What the new buyback and earnings mean for shareholders Zhuzhou CRRC Times Electric (SEHK:3898) has put two major developments on the table for investors to weigh: a fresh share repurchase program covering up to 3.6% of its issued share capital and recently released full year 2025 results. See our latest analysis for Zhuzhou CRRC Times Electric. The recent buyback launch and full year 2025 results sit alongside a 30 day share price return of 9.06% and year to date share price return of...

Why CK Hutchison Holdings Is On Investors’ Radar CK Hutchison Holdings (SEHK:1) has drawn fresh attention after a strong past year in the market, with its share price showing gains over the past month, past 3 months, and year to date. See our latest analysis for CK Hutchison Holdings. The recent 19.3% 3 month share price return and 17.8% year to date share price return, alongside a 68.9% 1 year total shareholder return, suggest momentum has been building as investors reassess growth prospects...

Meitu (SEHK:1357) has started repurchasing its own shares after shareholder approval for a program covering up to 10% of its issued capital, with management highlighting potential benefits for net asset value and earnings per share. See our latest analysis for Meitu. The buyback news comes after a weaker patch for the shares, with a 30 day share price return showing a decline of 29.52% and a year to date share price return showing a decline of 15.48%. However, the 3 year total shareholder...

Great Wall Motor (SEHK:2333) has outlined an expanded push into Europe, including a planned regional plant targeting 300,000 vehicles a year by 2030 and broader hybrid and combustion line ups to support higher overseas sales. See our latest analysis for Great Wall Motor. The latest HK$13.21 share price comes after a modest 1-day share price return of 1.46%. The 30-day and year to date share price returns show declines, yet the 1-year total shareholder return of 9.11% and 3-year total...

As global markets grapple with the implications of AI disruption and fluctuating economic data, Asian markets present a unique landscape where opportunities for undervalued stocks may arise. In this environment, identifying stocks trading below their intrinsic value can be crucial for investors seeking potential growth, as these equities often offer a compelling entry point amidst broader market uncertainties.

In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately received Chinese regulatory approval to begin human clinical trials of its self-developed complement factor B inhibitor CMS-D017 for complement-mediated kidney diseases. Together, the AI-enabled collaboration and first-in-human trial clearance highlight CMS’s push to build an innovative...

In early February 2026, Country Garden Holdings Company Limited reported that preliminary unaudited contracted sales attributable to shareholders for January reached approximately RMB 2.21 billion, covering about 0.28 million square meters of gross floor area. This monthly disclosure offers investors a timely snapshot of the developer’s recent contracting activity and physical sales volume in China’s property market. Next, we will examine how January’s RMB 2.21 billion in contracted sales...

Earnings and Dividend Moves Put NetEase in Focus NetEase (SEHK:9999) has drawn fresh attention after releasing its fourth quarter and full year 2025 results, alongside approving a higher ordinary cash dividend for shareholders and American Depositary Share holders. See our latest analysis for NetEase. NetEase shares trade at HK$187.3 after a recent 1 day share price return of 0.86%. However, the 30 day share price return shows a 13.13% decline compared with a 1 year total shareholder return...